drugset / Trial / NCT07482423

XVIE to Treat Androgenetic Alopecia (AGA)

NCT07482423 ↗

Phase 1/2 Not yet recruiting 30 enrolled Restore Biologics Holdings, Inc. dba Xtressé
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study tests whether XVIE, an investigational injectable product made from processed human amniotic fluid, is safe and may help regrow hair in adults with androgenetic alopecia (common pattern hair loss). XVIE contains growth factors and extracellular vesicles that may stimulate hair follicle activity. Thirty participants will be randomly assigned to receive either XVIE or a saline placebo injected into the scalp in two treatment sessions, 90 days apart. Neither participants nor study staff will know which treatment is being given. Participants will be followed for 6 months. The main goal is to evaluate safety. A secondary goal is to assess whether hair count, density, or coverage improves.

Timeline

Start
2026-05-01
Primary completion
2027-05-01
Completion
2027-05-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Decellularized allogeneic human amniotic fluid Unknown 2 ml Other

Indications